Zanubrutinib plus obinutuzumab for treating relapsed or refractory follicular lymphoma

Zanubrutinib, combined with an already licensed medicine, obinutuzumab, is in clinical development for the treatment of patients with relapsed or refractory B-cell follicular lymphoma. Follicular lymphoma is a slow-growing blood cancer that affects white blood cells. In follicular lymphoma, the affected white blood cells multiply abnormally and aggregate in certain parts of the body, such as the lymph nodes. Recurrence of lymphoma following remission, known as a relapse, and lymphoma unresponsive to therapy, known as refractory lymphoma, can make the condition more difficult to treat as treatment options are limited. The most common symptom of follicular lymphoma includes enlargement of lymph nodes in the neck, underarms, abdomen or groin. Typically follicular lymphoma is not considered curable, although patients can live for many years. Therefore, there is an unmet need for a more effective treatment option.